Group 1 - The core viewpoint of the article emphasizes that the creation of a management intelligent system is to empower rather than replace, aiming to reshape the value of healthcare through advanced technologies in the ophthalmology field [1] - The company has launched the AI intelligent product "Zhang Mulan Doctor," which assists in the entire process of ophthalmic diagnosis, from patient interaction to generating outpatient medical records and preliminary diagnoses [3] - The company has established partnerships with medical schools to enhance ophthalmology education and clinical practice, and its hospitals have been recognized as top-tier specialized hospitals by local health authorities [3] Group 2 - According to West Securities, the company is expected to achieve a revenue of 698 million yuan in basic ophthalmology in 2024, reflecting a year-on-year increase of 6.7% [5] - Huashan Securities noted that the company's established hospitals have a strong reputation and that newly acquired hospital assets are of high quality, which is expected to continuously enhance revenue and profits [5]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 依 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 Chaoju Eye Care Holdings Limited 朝聚眼科醫療控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2219） 於二零二五年六月六日舉行的 股東週年大會的投票表決結果 茲 提 述 朝 聚 眼 科 醫 療 控 股 有 限 公 司（「本公司」）日 期 為 二 零 二 五 年 四 月 二 十 八 日 的 通 函（「該通函」）。除 文 義 另 有 所 指 外，本 公 告 所 用 詞 彙 與 該 通 函 所 界 定 者 具 有 相 同 涵 義。 於 二 零 二 五 年 六 月 六 日 舉 行 的 股 東 週 年 大 會（「股東週年大會」）上，如 日 期 為 二 零 二 五 年 四 月 二 十 八 日 的 股 東 週 年 大 會 通 告 所 載，股 東 週 年 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 Chaoju Eye Care Holdings Limited 朝聚眼科醫療控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2219） 自願性公告 朝聚眼科旗下兩家醫院獲評為三級甲等醫院 一家醫院獲評為三級乙等醫院 本公告乃由朝聚眼科醫療控股有限公司（「本公司」，連同其附屬公司統稱為「本集團」） 自願刊發，旨在向本公司股東（「股東」）及潛在投資者告知本集團的最新業務發展。 本 公 司 董 事（「董 事」）會（「董事會」）欣 然 宣 佈，本 集 團 旗 下 的 內 蒙 古 朝 聚 眼 科 醫 院和包頭朝聚眼科醫院近日獲得內蒙古自治區衛生健康委員會評定為三級甲 等 專 科 醫 院。本 次 三 甲 評 審 的 結 果 不 僅 彰 顯 了 兩 家 醫 院 在 醫 療 服 務 和 技 ...

Summary of the Conference Call for Chaoyujian Eye Hospital Company Overview - **Company**: Chaoyujian Eye Hospital - **Industry**: Ophthalmology Key Points and Arguments Financial Performance - In 2024, the company's revenue increased by 2.6% year-on-year, while adjusted net profit decreased by 9.1% due to consumption downgrade and the ramp-up period of new hospitals [2][4] - The basic ophthalmology segment benefited from the acquisition of hospitals, leading to revenue growth, while the consumer ophthalmology segment faced pressure from price reductions in refractive surgeries, resulting in a gross margin decline of 6.5% [2][4] Surgical Trends - The volume of cataract surgeries increased significantly, with femtosecond laser cataract surgeries growing by 43%, which offset the impact of price declines due to centralized procurement [2][7] - High-end intraocular lens (IOL) usage increased, with high-end IOL revenue accounting for 60% in Q1 2025 [2] Market Dynamics - The full femtosecond laser technology is being promoted in multiple hospitals, but the price reduction of approximately 2,000 yuan has impacted revenue [2][6] - The company is actively responding to policy changes by enhancing hospital levels and expanding new business areas [2] Regional Performance - The impact of centralized procurement and Diagnosis-Related Group (DRG) policies varies by region, with Inner Mongolia managing to mitigate the effects through increased high-end IOL usage, while Hebei experienced slight losses due to the DIP policy [2][19][22] - Newly acquired hospitals contributed approximately 54 million yuan to overall revenue, but newly established hospitals are still in the ramp-up phase and have not yet turned profitable [12][13] Competitive Landscape - The ophthalmology merger and acquisition market is experiencing a downward shift in valuation, with slower IPO activity and reduced growth expectations affecting valuations [5][18] - The average price for full femtosecond laser procedures has decreased to a range of 16,800 to 19,800 yuan, with competitors having initiated price cuts earlier [11] Future Outlook - The company anticipates single-digit or double-digit revenue growth in 2025, but profit margins will need further evaluation based on Q2 and Q3 data [5][25] - The company aims to maintain a high dividend payout ratio of over 80% and will consider share buybacks based on market conditions [5][27] Consumer Behavior - The company is focusing on encouraging patients, particularly older demographics, to opt for high-end surgeries and IOLs through targeted marketing strategies [21][20] - The proportion of ICL (Implantable Contact Lens) remains low at approximately 7% of the overall refractive business [28] Challenges and Risks - The company faces challenges from consumption downgrade affecting gross margins, with expectations that the growth rate of refractive projects will be lower than in previous years [9][10] - The overall revenue structure in Q1 2025 remained flat, with basic ophthalmology showing positive growth while consumer ophthalmology faced pressure [10] Expansion Plans - The company plans cautious expansion, awaiting favorable conditions for potential acquisitions and new hospital openings [17] Additional Important Information - The company is actively working to mitigate the impact of DIP policies by increasing the proportion of self-paid services and promoting high-end products [20] - The performance of mature hospitals in Inner Mongolia showed a growth rate of 10% to 15%, while regions like Hebei and Zhejiang experienced declines [14]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 朝聚眼科醫療控股有限公司 呈交日期： 2025年4月29日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 不適用 | | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02219 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股份總數 | | | 事件 | 已 ...

朝聚眼科醫療控股有限公司 2024 年度環境、社會與管治（ESG）報告 | 報告編制說明 | 1 | | --- | --- | | 1. 關於朝聚眼科 4 | | | 公司概況 | 4 | | ESG 管理 | 5 | | 外部榮譽與認可 | 8 | | 2. 規範經營，加強企業管治 9 | | | 企業管治 | 9 | | 風險管理 10 | | | 商業道德 12 | | | 3. 服務患者，提升醫療品質 | 14 | | 醫療質量管理 14 | | | 醫療安全保障 16 | | | 醫療服務管理 19 | | | 藥品質量管理 | 22 | | 科研與創新 | 24 | | 4. 堅守責任，實現穩定運營 | 31 | | 負責任營銷 31 | | | 供應鏈管理 31 | | | 資訊安全與私隱保護 32 | | | 5. 員工為本，打造和諧職場 | 35 | | 員工權益與福利 35 | | | 人力資本發展 | 37 | | 職業健康與安全 44 | | | 6. 關愛環境，推動綠色發展 47 | | | 資源管理 | 47 | | 排放物管理 48 | | | 應對氣候變化 49 | | | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本通告的內容概不負責， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 通 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 依 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 Chaoju Eye Care Holdings Limited (A) 「動 議 ： 2 (i) 在下文第 (iii) 段 之 規 限 下，一 般 及 無 條 件 批 准 董 事 於 有 關 期 間（定 義 見 下 文）行 使 本 公 司 一 切 權 力，以 配 發、發 行 或 以 其 他 方 式 處 理 本 公 司 股 本 中 之 額 外 股 份（包 括 任 何 從 庫 存 中 出 售 或 轉 讓 的 庫 存 股 份）或 可轉 換為股 份的證 券、認 購 本 公 司 股 份 或 該 等 可 換 股 證 券 的 認 股 權 證或類似權利，以及作出或授予可能須行使該等權力的要約、協議及╱ 或 購 股 權（包 括 可 轉 換 為 本 公 司 股 份 的 債 券、認 股 權 證 及 債 權 ...

此乃要件 請即處理 閣下如 對本通函任何方面或應採取之行動 有任何疑問，應 諮 詢 閣下之持牌證 券 交 易 商 或 註 冊 證 券 機 構、銀 行 經 理、律 師、專 業 會 計 師 或 其 他 專 業 顧 問。 閣下如已出售或轉讓 名 下 全 部 朝 聚 眼 科 醫 療 控 股 有 限 公 司 的 股 份，應 立 即 將 本 通函及隨附之代表委任表格送交買主或承讓人或經手買賣或轉讓之持牌證券 交 易 商 或 註 冊 證 券 機 構 或 其 他 代 理 商，以 便 轉 交 買 主 或 承 讓 人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函之內容概不負責， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 通 函 之 全 部 或 任 何 部 份 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 之 任 何 損 失 承 擔 任 何 責 任。 Chaoju Eye Care Holdings Limited 朝聚眼科醫療控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2219） 建議授出發行新股及購回股份的一般授權 ...

Financial Performance - For the year ended December 31, 2024, the company reported revenue of RMB 1,405,454,000, representing an increase from RMB 1,369,505,000 in 2023, which is a growth of approximately 2.0%[5] - The gross profit for 2024 was RMB 611,302,000, with a gross margin of 43.5%, down from 45.4% in 2023[5] - The net profit for 2024 was RMB 186,210,000, resulting in a net profit margin of 13.2%, compared to 16.1% in the previous year[5] - The company reported a total equity of RMB 2,326,151,000 as of December 31, 2024, down from RMB 2,378,425,000 in 2023[5] - Total revenue reached RMB 1.405 billion, maintaining a healthy gross margin despite challenges from artificial lens procurement and DIP/DRG policies[15] - Net profit achieved RMB 186 million, with net cash flow from operating activities amounting to RMB 354 million, indicating strong financial health[15] - Total gross profit for the group was RMB 611.3 million for the year ended December 31, 2024, a decrease of 1.6% from RMB 621.1 million in 2023[37] - The company's adjusted net profit for the year ended December 31, 2024, is RMB 202.7 million, a decrease of 9.2% from RMB 223.1 million in 2023, with an adjusted net profit margin of 14.4% compared to 16.3% in the previous year[57] Operational Efficiency and Strategy - The company implemented a "Excellence Plan" to optimize management and resource allocation, enhancing operational efficiency across hospitals[12] - The company believes its cluster operation model enhances market penetration, operational efficiency, and profitability[9] - The company plans to enhance operational efficiency and service quality through systematic, standardized, professional, refined, and intelligent management strategies in 2025[16] - Marketing strategies were refined using data-driven approaches to improve marketing efficiency and ensure effective outreach to target patient groups[13] - Continuous investment in advanced medical equipment and precise pricing strategies for high-end ophthalmic services contributed to improved patient experiences[15] Market Expansion and Services - The company is focusing on expanding its consumer eye care services while maintaining its foundational eye care services, responding to the increasing consumer demand in China[7] - The group operates a network of 31 ophthalmology hospitals across 7 provinces, municipalities, and autonomous regions in China as of December 31, 2024[20] - The group aims to enhance market share in existing regions through strategic initiatives like the "Excellence Program" and "Wutong Program" while focusing on patient outcomes[19] - The group plans to continue investing in advanced medical equipment and treatment solutions to improve service quality and patient retention rates[25] - The consumption ophthalmology services accounted for 50.3% of total revenue in 2024, making it the primary revenue source for the group[24] - Basic ophthalmology services contributed approximately 49.6% to total revenue in 2024, marking it as another major revenue source[25] Human Resources and Talent Management - As of December 31, 2024, the group employed 1,464 full-time medical professionals, including 296 physicians, 625 nurses, and 543 other professionals[38] - The company has implemented systematic training and education programs for employees, ensuring a well-proportioned mix of medical professionals and enhancing clinical skills through both internal and external training[86] - The company is committed to maintaining gender diversity within its workforce and enhancing employee value as a key asset[124] Acquisitions and Investments - The group has made significant acquisitions in the healthcare sector, enhancing its service offerings and market presence[32] - The group has acquired multiple hospitals, including Bayannur Hospital and Beijing Clinic in September 2023, and Yinchuan Hospital in March 2023[32] - The group plans to continue expanding its network in the North China region and aims to acquire more hospitals in the near future[40] Financial Position and Cash Flow - The net cash inflow from operating activities for the year ended December 31, 2024, was RMB 354.4 million, down from RMB 372.6 million in 2023[61] - The company reported a net increase in cash and cash equivalents of RMB 317.3 million for the year ended December 31, 2024, compared to a decrease of RMB 481.3 million in 2023[61] - The total capital commitments as of December 31, 2024, amounted to approximately RMB 564 million, a decrease from RMB 715 million in 2023[66] Risk Management and Compliance - The company faces risks related to price controls and coverage limits under public health insurance plans, which may impact pricing of services and products[112] - The company has a credit risk management policy in place to monitor and manage potential losses from counterparties failing to meet obligations[77] - The company has maintained compliance with relevant laws and regulations, with no significant violations reported as of December 31, 2024[118] Shareholder and Governance - The company adopted a share incentive plan on May 10, 2022, granting a total of 16,330,994 shares to 311 employees and directors as of December 31, 2024, with a total allowable grant of 54,803,769 shares under the plan[85] - The company has established an audit committee consisting of three independent non-executive directors to oversee financial reporting and risk management[14] - All independent non-executive directors confirmed their independence for the period from January 1, 2024, to December 31, 2024[167] Environmental and Social Responsibility - The company has a commitment to environmental protection and has established policies for the proper handling and disposal of medical waste, ensuring compliance with applicable laws and regulations[115] - The company is committed to fulfilling social responsibilities and promoting employee welfare, aiming for sustainable growth[116]

朝聚眼科醫療控股有限公司 (Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立的有限公司） (Stock Code 股份代號: 2219) Dear registered shareholder(s), 15 April 2025 Arrangement of Electronic Dissemination of Corporate Communications Pursuant to Rule 2.07A of the Rules Governing The Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") under the expansion of paperless listing regime and electronic dissemination of corporate communications that came into effect on 31 December 2023, ...